Medline overview and recent share performance
Medline (MDLN) has attracted fresh attention after recent trading, with the share price at $44.28 and short term returns of 0.6% over the past day, 7.1% over the past week and 0.5% over the past month.
See our latest analysis for Medline.
That short term momentum sits within a wider pattern, with a 90 day share price return of 9.0% and a matching year to date share price return of 9.0%. This suggests interest in Medline has been steadily building.
If you are weighing Medline against other opportunities in healthcare, it can be useful to see how similar businesses are trading through our healthcare AI stocks screener, starting with 36 healthcare AI stocks.
With Medline trading at $44.28 alongside an indicated 21% discount to analyst targets and a 13% intrinsic discount, the key question is whether this points to a genuine opportunity or if the market is already pricing in future growth.
Price-to-earnings of 31x: Is it justified?
Medline currently trades on a P/E of 31x, which puts the share price at a premium to both its peer group average of 23x and the wider US Medical Equipment industry on 26.6x.
The P/E ratio compares the current share price to earnings per share, so a higher multiple usually reflects higher expectations for future profitability. With analysts forecasting earnings growth of 16.6% per year and revenue growth of 7.2% per year, the market is attaching a higher price to each dollar of Medline's current earnings than it does for many peers.
That premium sits alongside a few mixed signals. Revenue grew by 11.5% over the past year, but earnings growth over the same period was negative at 3.4% and net profit margins eased from 4.7% to 4.1%. Return on equity is described as low at 6% and is forecast to remain in that range at 10.1% in three years. This may not fully align with a P/E that is significantly above the peer and industry averages.
Compared with both its immediate peer group and the broader US Medical Equipment industry, Medline's 31x P/E appears expensive and leaves less room for disappointment if earnings or margins fall short of expectations.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-earnings of 31x (OVERVALUED)
However, investors still face risks if Medline's 31x P/E proves hard to support, or if profit margins and low return on equity fail to improve.
Find out about the key risks to this Medline narrative.
Another view: DCF suggests a different story
The P/E of 31x makes Medline look expensive, yet our DCF model points the other way, with a fair value estimate of $50.87 versus the current $44.28, or about a 13% gap. One model flags valuation risk, the other hints at a discount. Which do you consider more useful for your own process?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Medline for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 59 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals on valuation, risks and rewards, it helps to look at the facts yourself and move quickly to form your own stance by starting with the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If Medline has caught your eye, do not stop here. Broaden your watchlist with other clear, data backed ideas before the next opportunity passes by.
- Target reliable cash generators by scanning for companies with strong cash flows and robust balance sheets using the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for quality at a sensible price by checking stocks that look mispriced on fundamentals through the 59 high quality undervalued stocks.
- Zero in on under-the-radar opportunities by reviewing the screener containing 25 high quality undiscovered gems that may not yet be widely followed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com